These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 6861099

  • 1. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
    Creagan ET, O'Connell MJ, Kovach JS.
    Cancer; 1983 Aug 15; 52(4):615-8. PubMed ID: 6861099
    [Abstract] [Full Text] [Related]

  • 2. N-(phosphonacetyl)-L-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group.
    Bramwell V, Van Oosterom A, Mouridsen HT, Cheix F, Somers R, Thomas D, Rozencweig M.
    Eur J Cancer Clin Oncol; 1982 Jan 15; 18(1):81-4. PubMed ID: 6211362
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Erlichman C, Donehower RC, Speyer JL, Klecker R, Chabner BA.
    J Natl Cancer Inst; 1982 Feb 15; 68(2):227-31. PubMed ID: 6950156
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA, Capizzi RL, Muss HB, Smith S, Fernandes DJ, Homesley H, Loggie BW, Case L, Morris R, Russell GB, Richards F.
    Clin Cancer Res; 1996 Jul 15; 2(7):1107-14. PubMed ID: 9816275
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group.
    Paridaens R, Mouridsen HT, Palshof T, Cocconi G, Van Oosterom A, Rotmensz N, Sylvester R, Heuson JC, Rozencweig M.
    Eur J Cancer Clin Oncol; 1982 Jan 15; 18(1):67-70. PubMed ID: 6211361
    [Abstract] [Full Text] [Related]

  • 8. Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
    Markman M, Chan TC, Cleary S, Howell SB.
    Cancer Chemother Pharmacol; 1987 Jan 15; 19(1):80-3. PubMed ID: 3815730
    [Abstract] [Full Text] [Related]

  • 9. Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma.
    Morton RF, Creagan ET, Cullinan SA, Mailliard JA, Ebbert L, Veeder MH, Chang M.
    J Clin Oncol; 1987 Jul 15; 5(7):1078-82. PubMed ID: 3598611
    [Abstract] [Full Text] [Related]

  • 10. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
    Chan TC, Markman M, Cleary S, Howell SB.
    Cancer Res; 1986 Jun 15; 46(6):3168-72. PubMed ID: 3698032
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
    Van Echo DA, Diggs CH, Scoltock M, Wiernik PH.
    Cancer Treat Rep; 1980 Jun 15; 64(2-3):339-42. PubMed ID: 7407767
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
    Erlichman C, Vidgen D.
    Biochem Pharmacol; 1984 Oct 15; 33(20):3177-81. PubMed ID: 6487365
    [Abstract] [Full Text] [Related]

  • 16. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
    Erlichman C.
    Recent Results Cancer Res; 1980 Oct 15; 74():65-71. PubMed ID: 7444150
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
    Rosvold E, Schilder R, Walczak J, DiFino SM, Flynn PJ, Banerjee TK, Heim WJ, Engstrom PF, Ozols RF, O'Dwyer PJ.
    Cancer Chemother Pharmacol; 1992 Oct 15; 29(4):305-8. PubMed ID: 1537077
    [Abstract] [Full Text] [Related]

  • 18. Clinical trial of PALA and L-Alanosine in advanced colorectal carcinoma.
    O'Connell MJ, Rubin J, Schutt AJ, Moertel CG, Kvols LK.
    Cancer Treat Rep; 1983 Dec 15; 67(12):1141-2. PubMed ID: 6360350
    [No Abstract] [Full Text] [Related]

  • 19. PALA in advanced breast cancer. A phase II pilot study by the ECOG.
    Taylor SG, Davis TE, Falkson G, Keller AM.
    Am J Clin Oncol; 1982 Dec 15; 5(6):627-9. PubMed ID: 7165004
    [Abstract] [Full Text] [Related]

  • 20. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL, McAtee N, Steinberg SM, Hamilton JM, Murphy RF, Drake J, Chisena T, Balis F, Cysyk R, Arbuck SG.
    Cancer Res; 1993 Oct 15; 53(20):4828-36. PubMed ID: 8402669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.